Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TFEB | P19484 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | F9 | P00740 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5487009 | 1.00 | NFE2L2 (0.45) | NFE2L2KMT2ATFEBKDM4EF9 | |
| SCHEMBL15058014 | 0.84 | KMT2A (0.46) | NFE2L2KMT2AF9PLAUALDH1A1 | |
| SCHEMBL2314005 | 0.84 | KDM4E (0.45) | NFE2L2KMT2ATFEBKDM4EALDH1A1 | |
| SCHEMBL11939429 | 0.84 | KMT2A (0.58) | NFE2L2KMT2ATFEBKDM4EMEN1 | |
| SCHEMBL14672769 | 0.84 | KDM4E (0.45) | NFE2L2KMT2ATFEBKDM4EALDH1A1 | |
| SCHEMBL11939336 | 0.84 | KMT2A (0.58) | NFE2L2KMT2ATFEBKDM4EMEN1 | |
| SCHEMBL11939024 | 0.83 | KMT2A (0.45) | NFE2L2KMT2ATFEBKDM4EALDH1A1 | |
| SCHEMBL11939335 | 0.83 | KMT2A (0.45) | NFE2L2KMT2ATFEBKDM4EALDH1A1 | |
| SCHEMBL15606712 | 0.81 | KMT2A (0.41) | NFE2L2KMT2ATFEBKDM4EALDH1A1 | |
| SCHEMBL11939414 | 0.80 | NPSR1 (0.52) | KMT2AALDH1A1MEN1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288534-B2 | Process for the preparation a ruthenium complex | ROCHE PALO ALTO LLC (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2276725-B1 | NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METATHESIS REACTIONS | HOFFMANN LA ROCHE (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-7939668-B2 | Ruthenium complexes as catalysts for metathesis reactions | ROCHE PALO ALTO LLC (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939668-B2 | Ruthenium complexes as catalysts for metathesis reactions | ROCHE PALO ALTO LLC (US) | 2011-05-10 | — | — | US | disclosed |
| US-20100286403-A1 | PROCESS FOR THE PREPARATION A RUTHENIUM COMPLEX | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
| US-20090275714-A1 | New Ruthenium Complexes as Catalysts for Metathesis Reactions | ROCHE PALO ALTO LLC | 2009-11-05 | — | — | US | disclosed |
| US-20090275714-A1 | New Ruthenium Complexes as Catalysts for Metathesis Reactions | ROCHE PALO ALTO LLC | 2009-11-05 | — | — | US | disclosed |
| WO-2009124853-A1 | NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METATHESIS REACTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-15 | — | — | WO | disclosed |
| US-7241898-B2 | Metathesis catalysts | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-20050049417-A1 | Metathesis catalysts | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286403-A1 | PROCESS FOR THE PREPARATION A RUTHENIUM COMPLEX | CYP3A4, CYP3A5, CYP3A7 | NFE2L2 688/4885KMT2A 4269/4885TFEB 512/4885 |
| US-20050049417-A1 | Metathesis catalysts | CYP1B1, MSMO1, CYP1A1 | NFE2L2 85/4885KMT2A 2950/4885TFEB 1211/4885 |
| US-20090275714-A1 | New Ruthenium Complexes as Catalysts for Metathesis Reactions | HABP2, CYP3A7, ACE | NFE2L2 587/4885KMT2A 4270/4885TFEB 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.